Drug Resistance Mutations Group

The current members of the IAS–USA Drug Resistance Mutations Group are:

Victoria A. Johnson, MD (Chair)
Birmingham Veterans Affairs Medical Center
The University of Alabama at Birmingham School of Medicine
Birmingham, Alabama

Vincent Calvez, MD, PhD
Pierre et Marie Curie University
Pitié-Salpêtrière Hospital
Paris, France

Huldrych F. Günthard, MD
University Hospital of Zurich
Zurich, Switzerland

Roger Paredes, MD, PhD
HIV Unit and IrsiCaixa AIDS Research Institute
Hospital Universitari Germans Trias i Pujol
Badalona, Spain

Deenan Pillay, MD, PhD
Royal Free and University College Medical School
United Kingdom

Robert Shafer, MD
Stanford University Medical School
Stanford, California

Annemarie M. Wensing, MD, PhD
University Medical Center Utrecht
The Netherlands

Douglas D. Richman, MD (Vice-Chair)
Veterans Affairs San Diego Healthcare System and University of California San Diego
San Diego, California

DISCLOSURE INFORMATION

The members of the Drug Resistance Mutations Group are volunteers and are not compensated for their efforts on behalf of the group.

The current volunteer members of the Drug Resistance Mutations Group and their information or financial affiliations with commercial firms (as of November 2011) are:

Dr Johnson has received research support from Abbott Molecular, Roche Molecular Diagnostics, and Siemens Healthcare Diagnostics Inc.

Dr Calvez has served on advisory boards for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer, Inc, Roche, and ViiV Healthcare.

Dr Günthard has served as a consultant or medical advisor for Abbott Laboratories, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novartis AG, and Tibotec Pharmaceuticals; has received unrestricted research grants from Abbott Laboratories, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline, Merck Sharp & Dohme Corp, Tibotec Pharmaceuticals, and ViiV Healthcare; and has received travel grants from Abbott Laboratories, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline, Merck Sharp & Dohme Corp, Tibotec Pharmaceuticals, and ViiV Healthcare.

Dr Paredes has served as a consultant or medical advisor for Roche Diagnostics and ViiV Healthcare, and has received research grants awarded to IrsiCaixa and Lluita Contra la SIDA Foundations from Merck Sharp & Dohme Corp and ViiV Healthcare.

Dr Pillay has no relevant financial affiliations to disclose.

Dr Shafer has served as a consultant or medical advisor for Celera and Siemens Healthcare and has received grants from F. Hoffmann-La Roche Ltd and Gilead Sciences, Inc.

Dr Wensing has served as a consultant or medical advisor for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare; has received grants from Merck & Co, Inc, and ViiV Healthcare; and has received travel, accommodations, or meeting expenses from Bristol-Myers Squibb, Gilead Sciences, Inc, and Merck & Co, Inc.

Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc; received research grants or contracts from Merck & Co, Inc; and has been a stock options holder of CHIMERx and Idenix Pharmaceuticals, Inc.